The results displayed that the presented targeted system (AuNPs-AFPA-Dox) due to the presence of AS1411, which increased the entry of therapeutic agents to target cancer cells (MCF7 and 4T1) by detecting nucleolin on the surface of these cells, could differentiate between target and nontarget cells (CHO), unlike free Dox. This evidence concerns the gene NUCLEOLIN and cancer.